The oral acute myeloid leukemia (AML) treatment ‘Onureg’ can now be prescribed at general hospitals in Korea.

According to industry sources, BMS Korea’s new AML drug
Onureg tablet (azacytidine) has passed the drug committees of Asan Medical Center and Seoul National University Bundang Hospital and is also undergoing landing processes at major general hospitals in Korea.

As the company is currently negotiating drug prices with the National Health Insurance Service for reimbursement listing, preparations are in full swing to create an appropriate prescription environment.

Onureg was approved in Korea in March 2022 and passed the NHIS’s Cancer Disease Deliberation